Mga Batayang Estadistika
| LEI | 549300KPH77IVQVN2I21 |
| CIK | 1549084 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ekso Bionics Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 28, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 28, 2025 |
Ekso Bionics Reports Second Quarter 2025 Financial Results Exhibit 99.1 Ekso Bionics Reports Second Quarter 2025 Financial Results SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments |
|
| May 29, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| May 29, 2025 |
EKSO BIONICS HOLDINGS, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN (As of May 16, 2025) Exhibit 4.4 EKSO BIONICS HOLDINGS, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN (As of May 16, 2025) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide incentives to individuals who perform services for the Company, and • to promote the success of the Company’s business. The |
|
| May 29, 2025 |
As filed with the Securities and Exchange Commission on May 29, 2025 As filed with the Securities and Exchange Commission on May 29, 2025 Registration No. |
|
| May 21, 2025 |
Exhibit 99.1 Ekso Bionics Announces Reverse Stock Split SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m. |
|
| May 21, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 21, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizatio |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 16, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizatio |
|
| May 20, 2025 |
Exhibit 99.1 Ekso Bionics Announces Reverse Stock Split SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific t |
|
| May 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 5, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organization |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Ek |
|
| May 5, 2025 |
Ekso Bionics Announces First Quarter 2025 Financial Results Exhibit 99.1 Ekso Bionics Announces First Quarter 2025 Financial Results SAN RAFAEL, Calif., May 5, 2025 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments ● Stren |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☑ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37854 EKSO BIONICS 401(K) PLAN (Full title |
|
| April 15, 2025 |
April 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Mitchell Austin Re: Ekso Bionics Holdings, Inc. Registration Statement on Form S-3 File No. 333-286463 Filed on April 10, 2025 Acceleration Request Requested Date: April 17, 2025 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Pursu |
|
| April 10, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ekso Bionics Holdings, Inc. |
|
| April 10, 2025 |
As filed with the Securities and Exchange Commission on April 10, 2025 As filed with the Securities and Exchange Commission on April 10, 2025 Registration No. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 17, 2025 |
Form of Common Stock Purchase Warrant (Inducement Warrant) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 17, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| March 17, 2025 |
Exhibit 10.1 Ekso Bionics Holdings, Inc. 101 Glacier Point, Suite A San Rafael, CA (510) 984-1761 March 17, 2025 [Name of Holder] Re: Inducement Agreement to Exercise Warrants Dear Holder: Pursuant to this letter agreement (this “Agreement”), Ekso Bionics Holdings, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Series A common stock purchase warrant (“Series |
|
| March 3, 2025 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of re |
|
| March 3, 2025 |
Ekso Bionics Holdings, Inc. Insider Trading Policy Exhibit 19.1 EKSO BIONICS HOLDINGS, INC. INSIDER TRADING POLICY (Amended and Restated on February 24, 2025) A. POLICY OVERVIEW Ekso Bionics Holdings, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the C |
|
| March 3, 2025 |
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results Exhibit 99.1 Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results SAN RAFAEL, Calif., March 3, 2025 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlight |
|
| March 3, 2025 |
Jason Jones Offer Letter dated January 2, 2023 Exhibit 10.10 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW. 101 Glacier Point Suite A San Rafael, CA 94901 [email protected] January 2, 2023 Jason Jones [***] Promotion Offer by Ekso Bionics, Inc. Dear Jason, E |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 3, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| March 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 3, 2025 As filed with the U.S. Securities and Exchange Commission on March 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or other jurisdiction of incorporation or organization) (I |
|
| January 13, 2025 |
Exhibit 99.1 Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., January 13, 2025 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| December 13, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 12, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| November 14, 2024 |
EKSO / Ekso Bionics Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-ekso093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ekso Bionics Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282644301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| October 28, 2024 |
Ekso Bionics Announces Third Quarter 2024 Financial Results Exhibit 99.1 Ekso Bionics Announces Third Quarter 2024 Financial Results SAN RAFAEL, Calif., October 28, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024. Recent Highlights and Accomplishments ● Reported revenue of $4 |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3785 |
|
| October 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 28, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| September 3, 2024 |
Exhibit 4.3 SERIES B COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| September 3, 2024 |
Exhibit 1.1 3,100,000 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR 2,900,000 SHARES OF COMMON STOCK) SERIES A WARRANTS (EXERCISABLE FOR 6,000,000 SHARES OF COMMON STOCK) AND SERIES B WARRANTS (EXERCISABLE FOR 6,000,000 SHARES OF COMMON STOCK) OF EKSO BIONICS HOLDINGS, INC. UNDERWRITING AGREEMENT August 29, 2024 Craig-Hallum Capital Group LLC As the Representative of the Several und |
|
| September 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 29, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiza |
|
| September 3, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| September 3, 2024 |
Exhibit 4.2 SERIES A COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| August 30, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-281081 PROSPECTUS 3,100,000 Units, Each Unit Consisting of One Share of Common Stock, One Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock 2,900,000 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One Share of Common St |
|
| August 28, 2024 |
August 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Edwin Kim Re: Ekso Bionics Holdings, Inc. Registration Statement on Form S-1 File No. 333-281081 Acceleration Request Requested Date: August 29, 2024 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Se |
|
| August 28, 2024 |
August 28, 2024 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Ekso Bionics Holdings, Inc. Registration Statement on Form S-1 (Registration No. 333-281081) - Concurrence in Acceleration Request Ladies and Gentlemen: Craig-Hallum Capital Group LLC (“Craig-Hallum”), as representative of the underwriters for the referenced offeri |
|
| August 28, 2024 |
Form of Series A Warrant in connection with this offering Exhibit 1.1 [•] SHARES OF COMMON STOCK, [•] PRE-FUNDED WARRANTS (EXERCISABLE FOR [•] SHARES OF COMMON STOCK) [•] SERIES A WARRANTS (EXERCISABLE FOR [•] SHARES OF COMMON STOCK) AND [•] SERIES B WARRANTS (EXERCISABLE FOR [•] SHARES OF COMMON STOCK) OF EKSO BIONICS HOLDINGS, INC. UNDERWRITING AGREEMENT [•], 2024 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, |
|
| August 28, 2024 |
As filed with the Securities and Exchange Commission on August 28, 2024. As filed with the Securities and Exchange Commission on August 28, 2024. Registration No. 333-281081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EKSO BIONICS HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Nevada 3841 99-0367049 (State or other jurisdiction of incor |
|
| August 28, 2024 |
SERIES A COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Exhibit 4.10 SERIES A COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| August 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| August 28, 2024 |
Form of Series B Warrant in connection with this offering Exhibit 4.11 SERIES B COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| July 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| July 29, 2024 |
As filed with the Securities and Exchange Commission on July 29, 2024 As filed with the Securities and Exchange Commission on July 29, 2024 Registration No. |
|
| July 29, 2024 |
Form of Pre-Funded Warrant in connection with this offering Exhibit 4.9 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EKSO BIONICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| July 29, 2024 |
Form of Restricted Stock Unit Award under Amended and Restated 2014 Equity Incentive Plan Exhibit 10.7 RESTRICTED STOCK UNIT AGREEMENT EKSO BIONICS HOLDINGS, INC. THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is entered into as of the day of , 20 (the “Grant Date”) BETWEEN: EKSO BIONICS HOLDINGS, INC., a company incorporated pursuant to the laws of the State of Nevada (the “Company”), AND: [INSERT NAME], of [INSERT CITY], [INSERT STATE] (the “Grantee”). WHEREAS: A. The Board |
|
| July 29, 2024 |
Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024 Exhibit 99.1 Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024 SAN RAFAEL, Calif., July 29, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024. Recent Highlights and Accompli |
|
| July 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| July 29, 2024 |
As filed with the Securities and Exchange Commission on July 29, 2024. As filed with the Securities and Exchange Commission on July 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EKSO BIONICS HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Nevada 3841 99-0367049 (State or other jurisdiction of incorporation or organization) ( |
|
| July 29, 2024 |
Form of Underwriting Agreement Exhibit 1.1 SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) OF EKSO BIONICS HOLDINGS, INC. UNDERWRITING AGREEMENT , 2024 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: The undersigned, Ekso Bionics Holding |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 29, 2024 |
Amended and Restated 2014 Equity Incentive Plan Exhibit 10.4 EKSO BIONICS HOLDINGS, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN (As of June 6, 2024) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide incentives to individuals who perform services for the Company, and • to promote the success of the Company’s business. The |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 6, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorpor |
|
| June 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 6, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizatio |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Ek |
|
| April 29, 2024 |
Ekso Bionics Announces First Quarter 2024 Financial Results Exhibit 99.1 Ekso Bionics Announces First Quarter 2024 Financial Results SAN RAFAEL, Calif., April 29, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2024. Recent Highlights and Accomplishments ● Received final paym |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 18, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par |
|
| March 18, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 18, 2024 As filed with the U.S. Securities and Exchange Commission on March 18, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or other jurisdiction of incorporation or organization) ( |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☑ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37854 EKSO BIONICS 401(K) PLAN (Full title |
|
| March 4, 2024 |
Exhibit 99.1 Ekso Bionics Reports Annual Revenue of $18.3 Million Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 4, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights |
|
| March 4, 2024 |
Second Amendment to Loan Agreement with Pacific Western Bank, dated as of February 28, 2023. Exhibit 10.23 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of February 28, 2023, by and among PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and EKSO BIONICS, INC. and EKSO BIONICS HOLDINGS, INC. (individually and collectively referred to as “Borrower”). RECITALS Borrower and Bank are p |
|
| March 4, 2024 |
Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Ekso Bionics, Inc. Delaware Ekso Bionics GmbH Germany Ekso Bionics (Asia) Pte. Ltd. Singapore |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of re |
|
| March 4, 2024 |
Exhibit 4.9 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the “Company” or “we,” “us” or “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) |
|
| March 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 4, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| March 4, 2024 |
First Amendment to Loan Agreement with Pacific Western Bank, dated as of December 24, 2020. Exhibit 10.22 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of December 24, 2020, by and among PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and EKSO BIONICS, INC. and EKSO BIONICS HOLDINGS, INC. (individually and collectively referred to as “Borrower”). RECITALS Borrower and Bank are par |
|
| March 4, 2024 |
Ekso Bionics Holdings, Inc. Compensation Recovery Policy. Exhibit 97.1 EKSO BIONICS HOLDINGS, INC. COMPENSATION RECOVERY POLICY As adopted on October 24, 2023 Ekso Bionics Holdings, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’ |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| January 16, 2024 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 99.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 10, 2024, between Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| January 12, 2024 |
2,967,742 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272607 PROSPECTUS SUPPLEMENT (to Prospectus dated June 20, 2023) 2,967,742 Shares of Common Stock We are offering 2,967,742 shares of our common stock at a public offering price of $1.55 per share. These securities are being sold in this offering to certain purchasers under a securities purchase agreement dated January 10, 202 |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiza |
|
| January 5, 2024 |
Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results SAN RAFAEL, Calif., January 4, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 14, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3785 |
|
| October 26, 2023 |
Exhibit 99.1 Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38% Achieves Record Quarter of EVO Unit Sales SAN RAFAEL, Calif., October 26, 2023 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2023. Recent Highlights |
|
| October 26, 2023 |
Exhibit 10.2 Warranty Claim Lump Sum Arrangement This Warranty Claim Lump Sum Agreement (this “Agreement”) is entered into by and between EKSO Bionics Holdings, Inc., a Nevada corporation (the “Buyer”), and Parker-Hannifin Corporation, an Ohio corporation (the “Seller”, collectively with Buyer the “Parties” and each separately a “Party”) and is dated as of September 25, 2023. Recitals 1. Buyer and |
|
| October 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 26, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 29, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organ |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 17, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiza |
|
| August 18, 2023 |
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (the “Amendment”), is entered into as of August 17, 2023, by and among PACIFIC WESTERN BANK, a California state-chartered bank (the “Bank”), EKSO BIONICS, INC. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 28, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 28, 2023 |
EKSO BIONICS HOLDINGS, INC. Up to $5,000,000 of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272607 PROSPECTUS SUPPLEMENT (To Prospectus dated June 20, 2023) EKSO BIONICS HOLDINGS, INC. Up to $5,000,000 of Common Stock Ekso Bionics Holdings, Inc., or Ekso Bionics or we, has entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated as of October 9, |
|
| July 27, 2023 |
Ekso Bionics Report Record Revenues of $4.7 Million in Second Quarter 2023 Record number of EksoHealth devices booked in second quarter 2023 SAN RAFAEL, Calif., July 27, 2023 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 27, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 27, 2023 |
Amendment to Loan Agreement with Pacific Western Bank, dated as of July 3, 2023. Exhibit 10.3 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of July 3, 2023, by and among PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and EKSO BIONICS, INC. and EKSO BIONICS HOLDINGS, INC. (individually and collectively referred to as “Borrower”). RECITALS Borrower and Bank are parties |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 27, 2023 |
Amendment to Loan Agreement with Pacific Western Bank, dated as of March 28, 2023. Exhibit 10.2 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of March 28, 2023, by and among PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and EKSO BIONICS, INC. and EKSO BIONICS HOLDINGS, INC. (individually and collectively referred to as “Borrower”). RECITALS Borrower and Bank are parties |
|
| June 15, 2023 |
June 15, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Kyle Wiley Re: Ekso Bionics Holdings, Inc. Registration Statement on Form S-3 File No. 333-272607 Filed on June 12, 2023 Acceleration Request Requested Date: June 20, 2023 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Pursuant to R |
|
| June 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 12, 2023 As filed with the U.S. Securities and Exchange Commission on June 12, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or other jurisdiction of incorporation or organization) (I |
|
| June 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| June 12, 2023 |
Exhibit 10.1 EKSO BIONICS HOLDINGS, INC. AMENDMENT NO. 1 TO AT THE MARKET OFFERING AGREEMENT June 12, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the At the Market Offering Agreement, dated October 9, 2020 (the “Sales Agreement”), by and between Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”), and H.C. Wainwright & |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 8, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizatio |
|
| June 12, 2023 |
Exhibit 4.2 EKSO BIONICS HOLDINGS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establ |
|
| June 12, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) EKSO BIONICS HOLDINGS, INC. |
|
| June 12, 2023 |
As filed with the Securities and Exchange Commission on June 12, 2023 As filed with the Securities and Exchange Commission on June 12, 2023 Registration No. |
|
| April 28, 2023 |
ekso12312022x2023x04x17x UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DEF 14A 1 def14aannualmeeting682023.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant Check the appropriate box: Preliminar |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the C |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Ek |
|
| April 27, 2023 |
Ekso Bionics Announces 61% Increase in First Quarter 2023 Revenues Highest Quarterly Revenues in Company History SAN RAFAEL, Calif. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 27, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 20, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 26, 2023 |
Amended and Restated By-Laws of the Registrant EKSO BIONICS HOLDINGS, INC. Incorporated Under the Laws of the State of Nevada AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES Ekso Bionics Holdings, Inc. (the “Corporation”) shall maintain a registered office in the State of Nevada. The Corporation may also have other offices at such places, either within or without the State of Nevada, as the Board of Directors may from time to time designate or |
|
| April 26, 2023 |
Restated Articles of Incorporation of the Registrant RESTATED ARTICLES OF INCORPORATION OF EKSO BIONICS HOLDINGS, INC. Ekso Bionics Holdings, Inc., a corporation organized and existing under and by virtue of the provisions of the Nevada Revised Statutes of the State of Nevada (the “NRS”), DOES HEREBY CERTIFY: 1.That the name of the corporation is Ekso Bionics Holdings, Inc., and that the corporation was organized as a Nevada corporation pursuant to |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Ekso Bionics Holdings, Inc. |
|
| March 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2023 As filed with the U.S. Securities and Exchange Commission on March 29, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| March 28, 2023 |
Lease, dated July 15, 2022, between Don Tornberg and Ekso Bionics Inc. exhibit1022123122 |
|
| March 28, 2023 |
exhibit1014123122 LIC 19205 P-H AMEND 3 AC 4-17-19 THIRD AMENDMENT TO LICENSE AGREEMENT This Third Amendment to that certain License Agreement of October 15, 2012 ("Agreement") and the first amendment thereto of June 15,2014 and the second amendment thereto of December 1,2018, is entered into effective as of May 1,2019 (the "3'd Amendment Date") by and between Vanderbilt University, a not-for-prof |
|
| March 28, 2023 |
Exhibit 4.10 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the “Company” or “we,” “us” or “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specif |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 28, 2023 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| March 28, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Ekso Bionics, Inc. Delaware Ekso Bionics GmbH Germany Ekso Bionics (Asia) Pte. Ltd. Singapore |
|
| March 28, 2023 |
exhibit1015123122 LICENSE AGREEMENT BETWEEN VANDERBILT UNIVERSITY AND PARKER-HANNIFIN CORPORATION Table of Contents Article 1 DEFINITION OF TERMS . |
|
| March 28, 2023 |
Ekso Bionics Reports Fourth Quarter and Year End 2022 Results Ekso Bionics Reports Fourth Quarter and Year End 2022 Results SAN RAFAEL, Calif., March 28, 2023 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022. Recent Highlights and Accomplishments •Completed the acquisition of the Hu |
|
| March 28, 2023 |
Exhibit 10.11 101 Glacier Point Suite A San Rafael, CA 94901 Office: 510-984-1761 [email protected] October 26, 2022 Jerome Wong 127 Glen Drive Sausalito, CA 94965 Promotion Offer by Ekso Bionics, Inc. Dear Jerome, Ekso Bionics, Inc. is pleased to promote you from the position of Interim Chief Financial Officer to the position of Chief Financial Officer (CFO) and Corporate Secretary with Ekso Bio |
|
| March 28, 2023 |
Transitional Use Agreement, dated December 5, 2022, between Parker exhibit1023123122 EXECUTION VERSION 1 TRANSITIONAL USE AGREEMENT This Transitional Use Agreement (this “Agreement”) is made as of the 5th day of December, 2022 (the “Commencement Date”), by and between Parker-Hannifin Corporation, an Ohio corporation (hereinafter referred to as “Parker”), and EKSO Bionics Holdings, Inc. |
|
| March 28, 2023 |
Vanderbilt Assignment and Assumption Agreement between Ekso Bionics Holdings, Inc and Parker exhibit1016123122 NAI-1534280464v5 VANDERBILT ASSIGNMENT AND ASSUMPTION AGREEMENT This VANDERBILT ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2022 by and between EKSO BIONICS HOLDINGS, INC. |
|
| February 16, 2023 |
EXHIBIT 99.1 Human Motion and Control (A Product of Parker-Hannifin Corporation) Abbreviated Financial Statements For the Years Ended June 30, 2022 and 2021 and the Three Months Ended September 30, 2022 (unaudited) and 2021 (unaudited) Index to Abbreviated Financial Statements Page Independent Auditors’ Report 2-3 Abbreviated Financial Statements: Statements of Assets Acquired and Liabilities Assu |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 5, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorp |
|
| February 16, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On December 5, 2022, Ekso Bionics Holdings, Inc. (the “Company", "acquirer” or “Ekso”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Parker-Hannifin Corporation ("Seller"), pursuant to which the Company acquired certain assets related to the Seller’s human motion control business, and software appli |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 8, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 5, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| December 5, 2022 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN EKSO BIONICS HOLDINGS, INC. AND PARKER-HANNIFIN CORPORATION DATED AS OF December 5, 2022 TABLE OF CONTENTS Page i ARTICLE I DEFINITIONS ........................................................................................... 1 1.1 Certain Defined Terms .............................................................................. 1 1.2 Other D |
|
| December 5, 2022 |
Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego? Product Line From Parker Hannifin Corporation Broadens Ekso Bionics? product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif. |
|
| December 5, 2022 |
Exhibit 4.1 THIS SUBORDINATED PROMISSORY NOTE (THIS ?NOTE?) AND THE INDEBTEDNESS EVIDENCED BY THIS NOTE ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN SECTION 6 OF THIS NOTE. THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS A REGISTRATION STATEMENT UNDER THE ACT WITH RESPECT TO |
|
| December 5, 2022 |
Executive Chair Employment Agreement by and between the Company and Steven Sherman. December 5, 2022 Steven Sherman c/o Ekso Bionics Holdings, Inc. Re: Executive Chair Position Dear Mr. Sherman: This letter agreement sets forth the terms of your employment with Ekso Bionics Holdings, Inc. (the ?Company?) as Executive Chair of the Board of Directors of the Company (the ?Board?). 1.Term and Position. Your employment with the Company as Executive Chair shall commence on date hereof |
|
| November 3, 2022 |
Ekso Bionics Reports Third Quarter 2022 Results Quarterly Record of 33 EksoNR Bookings in Q3 2022 Ekso Bionics Reports Third Quarter 2022 Results Quarterly Record of 33 EksoNR Bookings in Q3 2022 SAN RAFAEL, Calif. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| November 3, 2022 |
Lease, dated July, 15, 2022, between Don Tornberg and Ekso Bionics, Inc. |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3785 |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 28, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 28, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 28, 2022 |
Ekso Bionics Reports Second Quarter 2022 Results Ekso Bionics Reports Second Quarter 2022 Results RICHMOND, Calif., July 28, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022. Recent Highlights and Accomplishments ?Reported revenue of $3.5 million in the second quarter of 2022, an |
|
| July 19, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 19, 2022 under the Securities Act of 1933, as amended. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or o |
|
| July 19, 2022 |
Calculation of Filing Fee tables EX-FILING FEES 2 exhibit1077192022.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. (Exact Name of the Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 9, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizatio |
|
| May 26, 2022 |
Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer Exhibit 99.1 Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer RICHMOND, Calif., May 26, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn. Mr. Glenn resigned |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2022 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the C |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the C |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Ek |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 28, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 28, 2022 |
Ekso Bionics Reports First Quarter 2022 Results Ekso Bionics Reports First Quarter 2022 Results RICHMOND, Calif., April 28, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022. Recent Highlights and Accomplishments ?Reported revenue of $2.6 million in the first quarter of 2022 ?St |
|
| March 10, 2022 |
William Shaw Transition Service Agreement dated March 10, 2022 Exhibit 10.1 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?) dated March 10, 2022, is by and between William Shaw (?Consultant?) and Ekso Bionics Holdings, Inc., a Nevada corporation (the ?Company?). Consultant and the Company are sometimes referred to herein collectively as the ?Parties?. WHEREAS, Consultant and the Company are Parties to that certain offer let |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 4, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| February 25, 2022 |
Calculation of Filing Fee tables Exhibit 107 Calculation of Filing Fee Tables FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Ekso Bionics Holdings, Inc. |
|
| February 25, 2022 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2022 under the Securities Act of 1933, as amended. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State |
|
| February 24, 2022 |
Exhibit 4.10 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the ?Company? or ?we,? ?us? or ?our?), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act? |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specif |
|
| February 24, 2022 |
Ekso Bionics Reports Fourth Quarter and Year End 2021 Results Ekso Bionics Reports Fourth Quarter and Year End 2021 Results RICHMOND, Calif., February 24, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments ?Reported record revenue of $4.1 mi |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 24, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| February 24, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Ekso Bionics, Inc. Delaware Ekso Bionics GmbH Germany Ekso Bionics (Asia) Pte. Ltd. Singapore |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* EKSO BIONICS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282644301 (CUSIP Nu |
|
| January 21, 2022 |
Exhibit 10.1 Executive Separation and Release Agreement This Executive Separation and Release Agreement (the ?Agreement?) is entered into by and between Ekso Bionics Holdings, Inc. (the ?Company?) and Jack Peurach (?Executive?) (collectively, ?Parties?). RECITALS WHEREAS, the Company and Executive intend by this Agreement to settle all legal rights and obligations arising out of or resulting from |
|
| January 21, 2022 |
Exhibit 10.3 1414 Harbour Way S Suite 1201 Richmond, CA 94804 Office: 510-984-1761x446 Fax: 510-550-3684 [email protected] February 22, 2021 Scott G. Davis *** *** Offer of Employment by Ekso Bionics, Inc. Dear Scott, 1 am pleased to offer you the position of EVP of Strategy and Corporate Development with Ekso Bionics, Inc. (the "Company"). You will report directly to Jack Peurach, CEO. The terms |
|
| January 21, 2022 |
Exhibit 99.1 Ekso Bionics Announces Leadership Transition Board Member Steven Sherman to be Appointed CEO EVP Scott Davis to be Appointed President and COO CEO Jack Peurach to Leave the Company Effective January 21, 2022 RICHMOND, Calif., January 21, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today |
|
| January 21, 2022 |
Employment Agreement, dated January 21, 2022, between the Company and Steven Sherman Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), made as of this 21st day of January, 2022 (the ?Effective Date?), is entered into by Ekso Bionics Holdings, Inc., a Nevada corporation (the ?Company?), and Steven Sherman (the ?Executive?). WHEREAS, the Company desires to employ the Executive, and the Executive desires to be employed by the Company. NOW, THEREFORE, in c |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2022 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 10, 2022 |
Exhibit 99.1 Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results Company Achieves Record Quarterly Revenue of $3.9 million to $4.1 million1 RICHMOND, Calif., January 10, 2022 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial result |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 25, 2021 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 28, 2021 |
Ekso Bionics Appoints Corinna E. Lathan, Ph.D. to its Board of Directors Exhibit 99.1 Ekso Bionics Appoints Corinna E. Lathan, Ph.D. to its Board of Directors RICHMOND, Calif. ? December 28, 2021 ? Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Corinna E. Lathan, Ph.D. to its Board of Directors, effective immediately. ?We are pleased to expand ou |
|
| November 2, 2021 |
Ekso Bionics Reports Third Quarter 2021 Results Ekso Bionics Reports Third Quarter 2021 Results RICHMOND, Calif., November 2, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021. Recent Highlights and Accomplishments ?Reported revenue of $3.0 million in the third quarter of 20 |
|
| November 2, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3785 |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 2, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| July 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 29, 2021 |
Ekso Bionics Reports Second Quarter 2021 Results Ekso Bionics Reports Second Quarter 2021 Results RICHMOND, Calif., July 29, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2021. Recent Highlights and Accomplishments ?Reported revenue of $2.2 million in the second quarter of 2021 ?Ac |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 21, 2021 |
Letter from OUM & Co. LLP to the Securities and Exchange Commission. EX-16.1 2 ex161.htm EX-16.1 Exhibit 16.1 July 21, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Ladies and Gentlemen: We have read Ekso Bionics Holdings, Inc.’s statements included under Item 4.01 of its Form 8‑K dated July 21, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K. Ve |
|
| July 21, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 15, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37854 EKSO BIONICS 401(K) PLAN (Full titl |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 10, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Ek |
|
| April 29, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Con |
|
| April 29, 2021 |
Ekso Bionics Reports First Quarter 2021 Results Ekso Bionics Reports First Quarter 2021 Results RICHMOND, Calif., April 29, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ?Company?), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2021. Recent Highlights and Accomplishments ?Reported revenue of $1.9 million in the first quarter of 2021, an |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 16, 2021 |
Exhibit 3.1 EKSO BIONICS HOLDINGS, INC. Incorporated Under the Laws of the State of Nevada BY-LAWS ARTICLE I OFFICES Ekso Bionics Holdings, Inc. (the ?Corporation?) shall maintain a registered office in the State of Nevada. The Corporation may also have other offices at such places, either within or without the State of Nevada, as the Board of Directors may from time to time designate or the busin |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 13, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizat |
|
| April 16, 2021 |
Amended and Restated 2014 Equity Incentive Plan Exhibit 10.1 EKSO BIONICS HOLDINGS, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN (AS OF APRIL 13, 2021) 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide incentives to individuals who perform services for the Company, and ? to promote the success of the Company?s business. T |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 3, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| February 26, 2021 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 26, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| February 25, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Incorporation Ekso Bionics, Inc. Delaware Ekso Bionics GmbH Germany Ekso Bionics (Asia) Pte. Ltd. Singapore |
|
| February 25, 2021 |
Ekso Bionics Reports Fourth Quarter and Year End 2020 Results Ekso Bionics Reports Fourth Quarter and Year End 2020 Results RICHMOND, Calif., February 25, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2020. Recent Highlights and Accomplishments •Reported revenue of $2.3 million i |
|
| February 25, 2021 |
Exhibit 4.10 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the ?Company? or ?we,? ?us? or ?our?), which the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). T |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ekso Bionics Holdings, Inc. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 25, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specif |
|
| February 25, 2021 |
Form S-8 (File No. 333-253526), filed on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 Registration Statement Under the Securities Act of 1933 Ekso Bionics Holdings, Inc. |
|
| February 25, 2021 |
Third Amendment to Lease Agreement dated June 16, 2020 between FPOC, LLC and Ekso Bionics, Inc. EX-10.30 3 exhibit1030.htm EX-10.30 Exhibit 10.30 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “3rd Amendment”) is made as of June 16, 2020, between FPOC, LLC, a California limited liability company (hereinafter called "Landlord"), and Ekso Bionics, Inc., a Delaware corporation (hereinafter called "Tenant"), having a place of business at 1414 Harbour Way So., Su |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* EKSO BIONICS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282644301 (CUSIP Numbe |
|
| February 11, 2021 |
Exhibit 1.1 Ekso Bionics Holdings, Inc. 3,902,440 Shares of Common Stock (par value $0.001 per share) Amended and Restated Underwriting Agreement February 8, 2021 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule A hereto 430 Park Avenue, 4th Floor New York, NY 10022 Ladies and Gentlemen: Ekso Bionics Holdings, Inc., a company incorporated under the laws o |
|
| February 11, 2021 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 11, 2021 |
Ekso Bionics Increases Previously Announced Bought Deal Offering of Common Stock to $40 Million Exhibit 99.2 Ekso Bionics Increases Previously Announced Bought Deal Offering of Common Stock to $40 Million RICHMOND, Calif., February 8, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced pub |
|
| February 11, 2021 |
Ekso Bionics Announces Closing of $40 Million Bought Deal Offering Exhibit 99.3 Ekso Bionics Announces Closing of $40 Million Bought Deal Offering RICHMOND, Calif., February 11, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of 3,902,440 shares of common stock of Ekso Bionics, at a p |
|
| February 11, 2021 |
Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock Exhibit 99.1 Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock RICHMOND, Calif., February 8, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2021 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 10, 2021 |
Ekso Bionics Holdings, Inc. 3,902,440 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-239203 PROSPECTUS SUPPLEMENT (To Prospectus dated June 26, 2020) Ekso Bionics Holdings, Inc. 3,902,440 Shares of Common Stock We are offering 3,902,440 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of co |
|
| February 9, 2021 |
Ekso Bionics Increases Previously Announced Bought Deal Offering of Common Stock to $40 Million Free Writing Prospectus dated February 9, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 8, 2021 Registration Statement No. |
|
| February 8, 2021 |
Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock FWP 1 tm215805d1fwp.htm FWP Free Writing Prospectus dated February 8, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 8, 2021 Registration Statement No. 333-239203 Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock RICHMOND, Calif., February 8, 2021 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leade |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2021 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 8, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 8, 2021 424B5 1 tm214998-1424b5.htm 424B5 TABLE OF CONTENTS The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any st |
|
| January 13, 2021 |
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2020 Financial Results Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2020 Financial Results RICHMOND, Calif. |
|
| January 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2021 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| December 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 29, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organi |
|
| December 31, 2020 |
December 30, 2020 Ekso Bionics’ Stockholders Elect Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors RICHMOND, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors by vo |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of |
|
| November 12, 2020 |
EKSO / Ekso Bionics Holdings, Inc. / Puissance Cross-Border Opportunities II LLC Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.4) Ekso Bionics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282644301 (CUSIP Number) Theodore Wang, Puissance Capital Fund (GP) LLC 950 Third Avenue, 25th Floor, New York, NY 10022 (212) 878-3702 (Name, Address an |
|
| November 12, 2020 |
DEF 14A 1 def14aannualmeeting12292020.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant Check the appropriate box: Prel |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 29, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| October 29, 2020 |
Ekso Bionics Reports Third Quarter 2020 Results Ekso Bionics Reports Third Quarter 2020 Results RICHMOND, Calif., October 29, 2020 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2020. Recent Highlights and Accomplishments •Reported revenue of $2.9 million in the third quarter of 20 |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3785 |
|
| October 23, 2020 |
Other Events, Shareholder Director Nominations - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 22, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiz |
|
| October 9, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 9, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiza |
|
| October 9, 2020 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT October 9, 2020 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Ekso Bionics Holdings, Inc., a corporation organized under the laws the State of Nevada (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1.Definitions. The terms that follow, when used |
|
| October 9, 2020 |
Ekso Bionics Holdings, Inc. Up to $7,500,000 Common Stock PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated June 26, 2020) Registration Statement No. |
|
| August 21, 2020 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 17, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organiza |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37854 Eks |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 30, 2020 Date of Report (date of earliest event reported) Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or other jurisdiction of incorporation or organizati |
|
| July 30, 2020 |
Ekso Bionics Reports Second Quarter 2020 Results Ekso Bionics Reports Second Quarter 2020 Results RICHMOND, Calif., July 30, 2020 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2020. Recent Highlights and Accomplishments •Reported revenue of $2.3 million in the second quarter of 2020 •Re |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 17, 2020 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 13, 2020 |
PROSPECTUS 873,852 Shares of Common Stock Issuable upon Exercise of Warrants Filed Pursuant to Rule 424(b)(1) Registration No. 333-239679 PROSPECTUS 873,852 Shares of Common Stock Issuable upon Exercise of Warrants This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 873,852 shares of our common stock they may acquire upon the exercise of warrants issued on Jun |
|
| July 9, 2020 |
July 9, 2020 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| July 2, 2020 |
Registration Statement - FORM S-1 S-1 1 tm2023834d1s1.htm FORM S-1 As filed with the Securities and Exchange Commission on July 2, 2020 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 99-0367049 (State or other jurisdiction of incorporation |
|
| June 26, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-239203 PROSPECTUS SUPPLEMENT (To Prospectus dated June 26, 2020) Ekso Bionics Holdings, Inc. 1,114,494 Shares of Common Stock Issuable Upon the Exercise of Warrants to Purchase Shares of Common Stock This prospectus relates to the offer and sale by us of up to 1,114,494 shares of our common stock issuable from time to time u |
|
| June 25, 2020 |
June 25, 2020 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| June 18, 2020 |
282644301 / Ekso Bionics Holdings Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37854 EKSO BIONICS 401(K) PLAN (Full titl |
|
| June 16, 2020 |
As filed with the Securities and Exchange Commission on June 16, 2020 Registration No. |
|
| June 16, 2020 |
Form of Subordinated Debt Security (included in Exhibit 4.21) Exhibit 4.21 EKSO BIONICS HOLDINGS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES Ekso Bionics Holdings, Inc. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939: Section 310 (a)(1) 6.9 (a)(2) 6.9 (a)(3) Not Applicable (a)(4) Not Applicable (b) 6.8, 6.10 Section 311 (a) 6.13 (b) 6.13 Section 312 (a) 7.1 |
|
| June 16, 2020 |
Form of Senior Debt Security (included in Exhibit 4.20) Exhibit 4.20 EKSO BIONICS HOLDINGS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES Ekso Bionics Holdings, Inc. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939: Section 310(a) (1) 6.9 (a)(2) 6.9 (a)(3) Not Applicable (a)(4) Not Applicable (b) 6.8, 6.10 Section 311(a) 6.13 (b) 6.13 Section 312(a) 7.1, 7.2 (b |
|
| June 16, 2020 |
282644301 / Ekso Bionics Holdings Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ekso Bionics Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282644301 (CUSIP Number) June 7, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2020 Ekso Bionics Holdings, Inc. (Exact Name of Registrant as specified in its charter) Nevada 001-37854 99-0367049 (State or Other Jurisdiction of Incorp |
|
| June 10, 2020 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 7, 2020, between Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| June 10, 2020 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
